Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study.
Pamela T SolimanShannon N WestinDavid A IglesiasBryan M FellmanYing YuanQian ZhangMelinda S YatesRussell R BroaddusBrian M SlomovitzKaren H LuRobert L ColemanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Everolimus, letrozole, and metformin resulted in 50% CB and 28% OR in women with recurrent EEC. Progesterone receptor-positive tumors may have better response; validation studies are needed.See related commentary by Madariaga et al., p. 523.